Tags |
|
|
Links |
|
|
Top Articles - The Wealth-Building Power of Capital Gains
Much ink has been spilt in the property investing literature debating the merits of property investing for capital gain, versus generating income by investing in positive cash flow propertie
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
s or buying and selling properties for profit (with the latter often referred to as ‘flipping’).
Each approach has merit, but each also has its downside. Buy-and-hold investors in residenti
Each approach has merit, but each also has its downside. Buy-and-hold investors in residenti
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
l property have to take the wealth they create in the form of capital gains and meet cash shortfalls from other sources. Those who chase yield (rental income) have turned (in Australia) to r
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
gional residential properties (where they have traded off capital gain in favour of yield) or commercial and industrial property (where yields are higher than residential property but the ri
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
k of vacancy is greater). Those who buy and sell properties are subject to market cycles and prone to financial loss if they mis-time the market.
Buying and holding to accumulate capital ga
Buying and holding to accumulate capital ga
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
n may not sound like a very attractive option: what’s appealing about accumulating wealth in the form of an invisible capital gain rather than as cash? A whole lot, as it turns out, particul
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
rly if you are in the so-called accumulation phase, where adding to your portfolio is the key objective. (This is in contrast to the drawdown phase, where you live off the returns from your
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
ssets rather than accumulating more assets).
Capital gains often produce larger and more tax-effective increases in wealth than could occur through realising income through high rents alone
Capital gains often produce larger and more tax-effective increases in wealth than could occur through realising income through high rents alone
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
or by buying and selling properties. This is because the impact of compounding is not eroded by the tax paid when income is realised.
If most of your return is in the form of yield, or you
If most of your return is in the form of yield, or you
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
rade in and out of the market you will gain income, but you will pay tax at your marginal rate each time that income lands in your bank account (that is, the income is realised). Buying and
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
olding property however, allows the property asset to grow in value (and your wealth with it) without tax being paid at each stage of that growth.
When a buy-and-hold investor eventually se
When a buy-and-hold investor eventually se
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
lls their asset (if they ever do) and the capital gains are eventually realised, the tax-effective power of compounding and capital gains produce far greater wealth than could be achieved th
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ough regular realised income alone.
US authors Thomas J. Stanley and William D. Danko state in their book The Millionaire Next Door that the average American millionaire realizes significan
US authors Thomas J. Stanley and William D. Danko state in their book The Millionaire Next Door that the average American millionaire realizes significan
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ly less than 10 percent of her or his net worth in annual income and has considerable wealth and substantial annual increases in wealth in unrealised form.
Billionaire investor Warren Buffe
Billionaire investor Warren Buffe
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
t is a keen (and highly-qualified) advocate of non-taxed capital gains. In his 1993 report to shareholders, Buffett pointed out the benefits of delayed taxes from allowing a capital gain to
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
ompound, and only paying tax when the final capital gain was realised. He compared this with the approach where an investor trades in and out of the market, paying tax on the gain from each
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
rade.
On Buffett's rendering, if a dollar doubled every year, and 35 per cent tax was paid on each doubling, it would take 27? years to reach a million dollars. On the other hand, if the do
On Buffett's rendering, if a dollar doubled every year, and 35 per cent tax was paid on each doubling, it would take 27? years to reach a million dollars. On the other hand, if the do
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
lar was allowed to double every year for those same 27? years and tax was only paid on the final capital gain, a post-tax gain of $130 million (!) would have been generated.
The arithmetic
The arithmetic
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
s as compelling as the results are obvious for investors: in Buffet’s words "…tax-paying investors will realise a far, far greater sum from a single investment that compounds internally at a
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
given rate than from a succession of investments compounding at the same rate."
High praise indeed for a patient buy-and-hold approach that produces invisible – but powerful – capital gains
High praise indeed for a patient buy-and-hold approach that produces invisible – but powerful – capital gains
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.toparticles.org.ua/article/139502/toparticles-The-WealthBuilding-Power-of-Capital-Gains.html">The Wealth-Building Power of Capital Gains</a>
BB link (for phorums):
[url=http://www.toparticles.org.ua/article/139502/toparticles-The-WealthBuilding-Power-of-Capital-Gains.html]The Wealth-Building Power of Capital Gains[/url]
Related Articles:
Increase Sales With Travel Incentives
Start New Projects With Bad Credit Business Loans
Top 10 European Countries for Real Estate Property Investors
Bookmark it:
|